Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Claire Harrison

Showing results (131-140 of 218) with videos related to

Pageof 22
Sort By:
Health and Quality of Life Outcomes|April 13, 2019
Development of a symptom assessment in patients with myelofibrosis: qualitative study findingsRuben A Mesa, Yun Su, Adrien Woolfson, et al.
Haematologica|November 20, 2025
JAK inhibitor selection in challenging scenarios of myelofibrosis: a reviewPankit Vachhani, Ruben Mesa, John Mascarenhas, et al.
Cancer Medicine|September 25, 2020
Depressive symptoms and myeloproliferative neoplasms: Understanding the confounding factor in a complex conditionLeslie Padrnos, Robyn Scherber, Holly Geyer, et al.
Biorxiv : the Preprint Server for Biology|June 3, 2024
Genomic factors shaping codon usage across the Saccharomycotina subphylumBryan Zavala, Lauren Dineen, Kaitlin J Fisher, et al.
Blood|March 13, 2009
Response criteria for essential thrombocythemia and polycythemia vera: result of a European LeukemiaNet consensus conferenceGiovanni Barosi, Gunnar Birgegard, Guido Finazzi, et al.
Haematologica|January 5, 2023
Long-term treatment with pacritinib on a compassionate use basis in patients with advanced myelofibrosisClaire Harrison, Abdulraheem Yacoub, Bart Scott, et al.
British Journal of Haematology|July 21, 2005
Guidelines for the diagnosis, investigation and management of polycythaemia/erythrocytosisMary F McMullin, D Bareford, P Campbell, et al.
Leukemia|July 24, 2025
QRISK3 score is predictive of thrombotic risk in patients with myeloproliferative neoplasmsAndrea Duminuco, Raj Vaghela, Sukhraj Virdee, et al.
G3 (Bethesda, Md.)|August 30, 2024
Genomic factors shaping codon usage across the Saccharomycotina subphylumBryan Zavala, Lauren Dineen, Kaitlin J Fisher, et al.
Haematologica|March 16, 2012
Experience with pegylated interferon α-2a in advanced myeloproliferative neoplasms in an international cohort of 118 patientsKrisstina Gowin, Prakash Thapaliya, Jan Samuelson, et al.
Pageof 22

Showing results (131-140 of 218) with videos related to

Sort By:
Pageof 22
Health and Quality of Life Outcomes|April 13, 2019
Development of a symptom assessment in patients with myelofibrosis: qualitative study findingsRuben A Mesa, Yun Su, Adrien Woolfson, et al.
Haematologica|November 20, 2025
JAK inhibitor selection in challenging scenarios of myelofibrosis: a reviewPankit Vachhani, Ruben Mesa, John Mascarenhas, et al.
Cancer Medicine|September 25, 2020
Depressive symptoms and myeloproliferative neoplasms: Understanding the confounding factor in a complex conditionLeslie Padrnos, Robyn Scherber, Holly Geyer, et al.
Biorxiv : the Preprint Server for Biology|June 3, 2024
Genomic factors shaping codon usage across the Saccharomycotina subphylumBryan Zavala, Lauren Dineen, Kaitlin J Fisher, et al.
Blood|March 13, 2009
Response criteria for essential thrombocythemia and polycythemia vera: result of a European LeukemiaNet consensus conferenceGiovanni Barosi, Gunnar Birgegard, Guido Finazzi, et al.
Haematologica|January 5, 2023
Long-term treatment with pacritinib on a compassionate use basis in patients with advanced myelofibrosisClaire Harrison, Abdulraheem Yacoub, Bart Scott, et al.
British Journal of Haematology|July 21, 2005
Guidelines for the diagnosis, investigation and management of polycythaemia/erythrocytosisMary F McMullin, D Bareford, P Campbell, et al.
Leukemia|July 24, 2025
QRISK3 score is predictive of thrombotic risk in patients with myeloproliferative neoplasmsAndrea Duminuco, Raj Vaghela, Sukhraj Virdee, et al.
G3 (Bethesda, Md.)|August 30, 2024
Genomic factors shaping codon usage across the Saccharomycotina subphylumBryan Zavala, Lauren Dineen, Kaitlin J Fisher, et al.
Haematologica|March 16, 2012
Experience with pegylated interferon α-2a in advanced myeloproliferative neoplasms in an international cohort of 118 patientsKrisstina Gowin, Prakash Thapaliya, Jan Samuelson, et al.
Pageof 22